Gene therapy of ALS with short interfering RNA

Brain and Nerve

Volumn 59, Issue 10, 2007, Pages 1187-1194

  Yokota, Takanori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Agonaute; Gene therapy; RNAi; shRNA; siRNA

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; DOUBLE STRANDED RNA; SMALL INTERFERING RNA;

AMYOTROPHIC LATERAL SCLEROSIS; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETIC TRANSCRIPTION; NONHUMAN; REVIEW;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; RNA INTERFERENCE; RNA, DOUBLE-STRANDED; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE; VIRUSES;

EID: 35348942396     PISSN: 00068969     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, et al: TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436: 740-744, 2005
2. Tomari Y, Zamore PD: Perspective: machines for RNAi. Genes Dev 19: 517-529, 2005.
3. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD: Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123: 607-620, 2005
4. Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001
5. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 29: 550-553, 2002
6. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, et al: ANG mutations segregate with familial and "sporadic" amyotrophic lateral sclerosis. Nat Genet 38: 411-413, 2006
7. Saito Y, Yokota T, Mitani T, Ito K, Anzai M, et al: Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model. J Biol Chem 280: 42826-42830, 2005
8. Shefner JM, Reaume AG, Flood DG, Scott RW, Kowall NW, et al: Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology 53: 1239-1246, 1999
9. Uchiyama S, Shimizu T, Shirasawa T: CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J Biol Chem 281: 31713-31719, 2006
10. Yokota T, Miyagishi M, Hino T, Matsumura R, Tasinato A, et al: siRNA-based inhibition of superoxide dismutase expression; potential use in familial Amyotrophic lateral sclerosis. Biochem Biophys Res Com 314: 283-291, 2004
11. Schwartz DS, Ding H, Kennington L, Moore JT, Schelter J, et al: Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genetics 446: 864-865, 2006
12. Kubodera T, Yokota T, Ishikawa K, Mizusawa H: New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides 15: 298-302, 2005
13. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, et al: Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8: 1343-1349, 2005
14. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, et al: Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288: 335-339, 2000
15. Davidson BL, Harper SQ: Viral delivery of recombinant short hairpin RNAs. Methods Enzymol 392: 145-173, 2005
16. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, et al: Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11: 429-433, 2005
17. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, et al: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11: 423-428, 2005
18. Miller TM, Kaspar BK, Kops GJ, Yamanaka K, Christian LJ, et al: Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol 57: 773-776, 2005
19. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, et al: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2056-2058, 2007
20. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, et al: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541, 2006
21. Thakker DR, Natt F, Husken D, Maier R, Muller M, et al: Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain using nonviral RNA interference. Proc Natl Acad Sci U S A 101: 17270-17275, 2004
22. Guissouma H, Froidevaux MS, Hassani Z, Demeneix BA: In vivo siRNA delivery to the mouse hypothalamus confirms distinct roles of TR beta isoforms in regulating TRH transcription. Neurosci Lett 406: 240-243, 2006
23. Luo MC, Zhang DQ, Ma SW, Huang YY, Shuster SJ, et al: An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 1: 1-8, 2005
24. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, et al: Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116: 2290-2296, 2006
25. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, et al: Antobody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717, 2005
26. McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, et al: Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015, 2006
27. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, et al: Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res. 10: 3667-3677, 2004
28. Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, et al: Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 24: 10040-10046, 2004.
29. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, et al: Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43, 2007
30. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21: 635-637, 2003
31. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, et al: 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3: 199-204, 2006
32. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, et al: Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12: 1179-1187, 2006
33. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, et al: Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12: 1197-1205, 2006